Sodium-dependent phosphate transporter NaPi2b is involved in transport of
Introduction. Sodium-dependent phosphate transporter NaPi2b (SLC34A2, NaPiIIb, Npt2) is normally expressed in mammalian small intestine at the apical side of enterocyte's brush-border membranes. NaPi2b participates in the transcellular inorganic phosphate (P i ) absorption, contributing to the maintenance of phosphate homeostasis in the organism [1] [2] [3] . The studies on conditional knockout mice demonstrated that NaPi2b contributes to > 90 % of total active phosphate absorption [4] .
The attempts to generate NaPi2b homozygous deficient mice resulted in death of embryos in uterus soon after implantation, indicating that NaPi2b is the major P i transporter during mouse embryonic development [5] .
The expression of NaPi2b mRNA was revealed by Northern blot analysis in many human normal tissues including lung, kidney, liver, prostate, pancreas, testis, ovary, thymus [1, 2] . The expression of NaPi2b on protein level has been detected in normal human salivary glands by Western blotting with polyclonal antibodies against NaPi2b [6] .
It was reported that alterations in NaPi2b expression are linked to several human abnormalities. In lungs, NaPi2b is the only phosphate transporter that is highly expressed, and it is involved in uptake of phosphate for synthesis of surfactant proteins. Deregulation of the NaPi2b transporter function as a result of mutations in SLC34A2 gene may lead to the pulmonary alveolar microlithiasis, autosomal recessively inherited disease, characterized by deposition of calcium-phosphate precipitates in lungs [7, 8] .
The increased expression of SLC34A2 gene in cancer was detected in ovarian and papillary thyroid tumors [9, 10] . Recently, it has been demonstrated that the expression level of SLC34A2 gene is increased in human breast tumors [11] . Low dietary P i uptake, wellknown regulator of NaPi2b expression and function, was shown to cause lung tumorigenesis in K-ras (LA1) model mice on the background of increased NaPi2b expression [12] .
Previously, we identified NaPi2b as an ovarian cancer antigen MX35 by screening cDNA library from OVCAR3 cells with the MX35 antibody [13] . This antibody was generated from mice immunized with a cocktail of human ovarian carcinoma cells and showed reactivity with approximately 90 % samples of human epithelial ovarian cancers [14] . Heterogeneous expression profile of MX35/NaPi2b protein was further confirmed for epithelial ovarian tumors of different histomorphological types [15] . The radiolabelled MX35 antibody was used in clinical trials and was shown to possess the therapeutic effect in patients with ovarian cancer [16, 17] . However, the unlabelled MX35 antibody did not have any therapeutic effect on tumor growth in model mice [18] .
Playing an essential role in phosphate homeostasis in a human body NaPi2b is considered as a target for inhibition of hyperphosphatemia in patients with chronic renal failure [19] . There are some P i -containing compounds that have been reported as inhibitors of sodiumdependent phosphate transport including phosphonoformic acid, 2V-phosphophloretin, and JTP-59557 [20] [21] [22] . But all mentioned inhibitors are not strictly specific for sodium-dependent phosphate transport mediated by NaPi2b.
The identification of MX35 ovarian cancer antigen as sodium-dependent transporter NaPi2b gave an opportunity to investigate the impact of specific antibody MX35 on the transport function of NaPi2b. This study aimed to analyze the effect of MX35 antibody on the functioning of sodium-dependent phosphate transporter NaPi2b using cellular models and to determine whether this antibody can function as a specific inhibitor of NaPi2b-mediated phosphate transport.
Materials and methods. Constructs, stable cell line generation. Generation of HEK293 cells stably expressing wild type and mutant forms of NaPi2b was previously described [23] . Briefly, human NaPi2b cDNA (NaPi2b_WT) was cloned into pcDNA3.1(+) («Invitrogen», USA) in the frame with EE-tag. A mutant form of NaPi2b (pcDNA3.1(+)/NaPi2b_T330V) was obtained by site-directed mutagenesis. HEK293 cells were transfected with recombinant plasmids (pcDNA3.1(+)/NaPi2b_WT, pcDNA3.1(+)/NaPi2b_ T330V or empty vector) using FuGene («Roshe», Switzerland). Cells were cultured in the presence of G418 antibiotic («Gibco», UK) at the concentration of 1 mg/ml for 7-10 days to eliminate nontransfected cells before splitting.
Phosphate uptake analysis. HEK293 cells were placed on 96-well plate at 3×10 4 cells/well and incubated with the MX35 antibody for different time (6, 12, 24, 48, 96 h). The MX35 antibody was kindly provided by Dr. Gerd Ritter (Ludwig Institute for Cancer research, USA). After medium was removed cells were washed 3 times with 200 ml of wash solution (137 mM NaCl, 5.4 mM KCl, 2.8 mM CaCl 2 , 1.2 mM MgSO 4 , 14 mM Tris HCl (pH 7.4)). 50 ml of assay solution (0.1 mM KH 2 PO 4 , 137 mM NaCl, 5.4 mM KCl, 2.8 mM CaCl 2 , 1.2 mM MgSO 4 , 14 mM Tris HCl (pH 7.4)) with [
33 P] orthophosphate (1 mCi/ml) was added to each well and incubated at room temperature. Then, assay solution was removed and cells were rinsed 3 times with 150 ml of ice-cold stop solution (137 mM NaCl, 14 mM Tris HCl (pH 7.4)). Cells were lysed in 50 ml of lysis buffer (0.01 M Tris HCl, pH 7.5, 0.15 M NaCl, 0.01 M MgCl 2 , 0.5 % NP-40) and 25 ml of cell lysate was used to determine radioactivity in a liquid scintillation counter («Perkin Elmer», USA). The rest of cell lysate was used to determine protein concentration using BCA protein assay kit («Pierce Biotechnology», USA). To inhibit sodium-dependent phosphate transport phosphonoformic acid («Sigma», USA) was added to the assay solution at 5 mM concentration.
Western blot analysis. HEK293 cells were lysed in buffer containing 10 mM Tris-HCI, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 0.5 % NP-40 and a mixture of Halt Protease Inhibitor Cocktail («Pierce», USA). Protein concentration was estimated by Comassie Assay («Pierce»). Protein samples were separated by 10 % SDS/PAGE and electrotransferred on polyvinylidene difluoride (PVDF) membrane («Millipore», USA). The membranes were blocked with 3 % BSA in 1 1 ´ PBST for 1 h at RT and incubated with the MX35 antibody at 4 °C overnight. After incubation with HRP-conjugated goat anti-mouse IgG («Promega», USA) the membranes were developed using the ECL system («Amersham», Sweden) and then exposed to Agfa X-ray film.
Statistical analysis. Data are provided as means ± ± SEM. All experiments were repeated 3 times; in all repetitions qualitatively similar data were obtained.
Results and discussion. Sodium-dependent phosphate transporter NaPi2b, which plays an essential role in the maintenance of phosphate homeostasis in the human body, was revealed as ovarian cancer marker MX35 [13] . It has been shown that the radiolabelled MX35 antibody recognizing NaPi2b has therapeutic effect in patients with ovarian cancer and F(ab) 2 fragments of the MX35 antibody specifically localize in micrometastatic loci within peritoneal cavity [16, 17] . Knowledge about the function of MX35 antigen provided the basis for the investigation of the MX35 antibody impact on the phosphate transport function of MX35/NaPi2b protein.
To investigate the function of NaPi2b as a transporter of inorganic phosphate we applied a phosphate uptake assay using HEK293 cells expressing the wild type and mutant form of NaPi2b as well as HEK293 cells transfected with empty pcDNA3.1(+) plasmid as a control. In the predicted topology of NaPi2b, both Nand C-terminal tails face cytoplasm, exposing loops of various length to the extracellular and intracellular compartments including a large extracellular loop (188-361 aa). Previously, we have shown that the epitope recognized by MX35 antibody is located within the predicted extracellular domain (311-340 aa) [13, 24] . Further studies have shown that the mutation T330V in the large extracellular loop of NaPi2b transporter is crucial for the recognition of NaPi2b by the MX35 antibody [23] . Western blot analysis of lysates of cell lines stably expressing the wild type and mutant form (NaPi2b_T330V) of transporter clearly indicated that mutant NaPi2b_T330V was not recognized by the MX35 antibody whereas both wild type and mutant form were recognized well by the EE-tag specific antibody (Fig. 1 ).
We applied a phosphate uptake assay to investigate the NaPi2b transport function in the cells expressing wild type NaPi2b and in the control cell line. In timecourse study, the human NaPi2b-mediated P i uptake increased linearly up to 30 min, thus 15 min uptake time was used to evaluate phosphate uptake in further experiments (data not shown).
At this uptake time we observed 2.5-fold increase in P i uptake in the cells expressing wild type NaPi2b (10.6 ± 0.6 nmol/mg protein) in contrast to the cells transfected with empty pcDNA3.1(+) plasmid (4.2 ± ± 0.4 nmol/mg protein) (Fig. 2) . The cells expressing the mutant form NaPi2b_T330V transported inorganic phosphate with the same efficiency as the cells expressing the wild type of NaPi2b (11.5 ± 0.7 nmol/mg protein) (Fig. 2) . The use of well-known inhibitor of sodium-dependent phosphate transport phosphonofor- mic acid at 5 mM concentration in assay solution led to the total abolishment of P i uptake in all the investigated cell lines (Fig. 2) .
To determine the effect of MX35 antibody on NaPi2b-mediated transport we performed the phosphate uptake experiments for all mentioned cell lines after incubation with the MX35 antibody at different concentrations (5, 10, 20, and 50 mg/ml) and different time (6, 12, 24, 48 , 96 h) (data not shown). We detected a considerable inhibition of phosphate uptake in the cells expressing wild type of NaPi2b incubated for 24h with the MX35 antibody at concentration of 50 mg/ml. In this case 1,8-fold decrease in sodium-dependent phosphate uptake was observed for the wild type NaPi2b (incubation with antibody -10.52 ± 0.65 nmol/mg; incubation without antibody -5.6 ± 0.45 nmol/mg). At the same time phosphate transport in the cell line transfected with empty pcDNA3.1(+) plasmid remained unchanged (incubation with antibody -4.5 ± 0.3 nmol/ mg protein; incubation without antibody -4.2 ± ± 0.4 nmol/mg) (Fig. 3) .
To confirm the specificity of this inhibition we evaluated the effect of MX35 antibody on the cells expressing the mutant form NaPi2b_T330V, which is not recognized by the MX35 antibody. No significant changes were detected in the phosphate uptake measurements in the cells expressing NaPi2b_T330V after incubation with the MX35 antibody (11.5 ± 0.7 nmol/ mg protein; 10 ± 0.5 nmol/mg protein) (Fig. 3) . Our data clearly demonstrate that the MX35 antibody specific to NaPi2b transporter significantly decreased sodium-dependent phosphate uptake in the cellular models used in this study.
The mechanism of remarkable inhibition of sodium-dependent phosphate transport by the antibody specific to extracellular domain of NaPi2b still remains unknown. It should be further investigated whether the incubation of the cells expressing NaPi2b with the MX35 antibody may lead to down regulation of NaPi2b protein decreasing the number of transporter units on cell surface or the binding of MX35 antibody can cause conformational changes in transporter structure affecting its function and vice versa it can prevent conformational changes necessary for transporter functioning.
Conclusions. Using cellular models expressing the wild type and mutant NaPi2b_T330V transporter we showed that the MX35 antibody directed against NaPi2b significantly decreased phosphate uptake mediated by NaPi2b and, thus, can be considered as a specific inhibitor of NaPi2b transport function.
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